Additionally, the EGFR/RAS/RAF/MEK/ERK pathway and its downstream effectors have primarily been studied in the context of squamous cell carcinomas, which comprise 85–90% of cervical cancers (Pappa et al, 2006). This evidence concerns the gene EGFR and squamous cell carcinoma.